1. Home
  2. ALRS vs CELC Comparison

ALRS vs CELC Comparison

Compare ALRS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALRS
  • CELC
  • Stock Information
  • Founded
  • ALRS 1879
  • CELC 2011
  • Country
  • ALRS United States
  • CELC United States
  • Employees
  • ALRS N/A
  • CELC N/A
  • Industry
  • ALRS Major Banks
  • CELC Medical Specialities
  • Sector
  • ALRS Finance
  • CELC Health Care
  • Exchange
  • ALRS Nasdaq
  • CELC Nasdaq
  • Market Cap
  • ALRS 468.2M
  • CELC 440.0M
  • IPO Year
  • ALRS 2019
  • CELC 2017
  • Fundamental
  • Price
  • ALRS $22.43
  • CELC $13.04
  • Analyst Decision
  • ALRS Hold
  • CELC Strong Buy
  • Analyst Count
  • ALRS 5
  • CELC 6
  • Target Price
  • ALRS $23.20
  • CELC $30.67
  • AVG Volume (30 Days)
  • ALRS 75.0K
  • CELC 196.9K
  • Earning Date
  • ALRS 07-23-2025
  • CELC 08-13-2025
  • Dividend Yield
  • ALRS 3.77%
  • CELC N/A
  • EPS Growth
  • ALRS 118.02
  • CELC N/A
  • EPS
  • ALRS 1.08
  • CELC N/A
  • Revenue
  • ALRS $224,218,000.00
  • CELC N/A
  • Revenue This Year
  • ALRS $40.50
  • CELC N/A
  • Revenue Next Year
  • ALRS $3.54
  • CELC N/A
  • P/E Ratio
  • ALRS $20.58
  • CELC N/A
  • Revenue Growth
  • ALRS 35.73
  • CELC N/A
  • 52 Week Low
  • ALRS $15.78
  • CELC $7.58
  • 52 Week High
  • ALRS $24.41
  • CELC $19.77
  • Technical
  • Relative Strength Index (RSI)
  • ALRS 63.76
  • CELC 60.10
  • Support Level
  • ALRS $21.50
  • CELC $12.48
  • Resistance Level
  • ALRS $22.27
  • CELC $13.60
  • Average True Range (ATR)
  • ALRS 0.46
  • CELC 0.74
  • MACD
  • ALRS 0.05
  • CELC 0.04
  • Stochastic Oscillator
  • ALRS 100.00
  • CELC 75.91

About ALRS Alerus Financial Corporation

Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and Mortgage. It provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services as well as wealth management services, including financial & estate planning, trust, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: